Last reviewed · How we verify
Beclomethasone dipropionate breath-actuated inhaler
Beclomethasone dipropionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release.
Beclomethasone dipropionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Beclomethasone dipropionate breath-actuated inhaler |
|---|---|
| Also known as | BDP |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
As an inhaled corticosteroid, beclomethasone dipropionate acts locally in the lungs to inhibit inflammatory cell activation and reduce production of inflammatory cytokines and mediators. The breath-actuated formulation delivers the drug directly to the airways upon inhalation, minimizing systemic exposure while maximizing local anti-inflammatory effects in the respiratory tract.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia/hoarseness
- Tremor
- Headache
- Nervousness/anxiety
Key clinical trials
- Asthma Research in Children and Adolescents
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma (PHASE3)
- A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma (PHASE3)
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma (PHASE3)
- Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma (PHASE3)
- A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: